

DEC 27 2000

TECH CENTER 1600/200

SER 1644 # 8 1/9/01 Docket No. 157-475-7-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

W. Marasco, et al.

Serial No.:

09/522,727

Filed:

For:

March 10, 2000

Group No.: Examiner Ros

Vo.: 1644 Roark, J.

TECH CENTER 1600/2800

INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

The Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Certificate of Mailing

I hereby certify that the following items are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to BOX SEQUENCE, Commissioner of Patents and Trademark, Washington, DC 20231, on this 6th day of December, 2000:

- 1. Computer Readable Copy Containing Nucleotide Sequence;
- 2. Paper Copy Containing Nucleotide Sequence;
- 3. Statement that "Sequence Listing" and Computer Readable Copy are the same and/or that Papers Submitted Includes No New Matter;
 - 4. Transmittal of Substitute Specification Sheets;
 - 5. Substitute Specification Sheets (Pages 44-65).

Maria R. Valinch

avia R. Valinch



Docket No. 157-47577-C

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re a	pplication of:	W. Marasco, et al.				UEC 18 2008	
Serial No.: Filed:		09/522,727 March 10, 2000		Group No.: Examiner	1644 Roark, J.	TEOM COMMERT 16000/2900	
			ED CONT	EXAMINET ROARK, J. ED CONTROL OF IMMUNE REACTIONS			
Comm	mendment hissioner for Pat ngton, D.C. 202						
		AMENDMENT	TRANSM	ITTAL			
1.	Transmitted he	rewith is an amendment for the	nis application	on.		•	
		ST	ATUS				
2.	[] [X]	l entity. A statement: is attached. was already filed. han a small entity.					
		EXTENSIO	ON OF TER	M			
NOTE:	Non-Final Office	e in Patent Cases (Supplement Ame Action, an extension of time is not the shortened statutory period.					
		CERTIFICATE OF MAILING/	FRANSMISS	ION (37 C.F.R. 1.8	B(a))		
I hereby	certify that, on the	date shown below, this corresponde	ence is being:				
	MA	AILING		FAC	SIMILE		
X	with sufficient po envelope addresse	e United States Postal Service stage as first class mail in an ed to the Assistant		transmitted by fac Trademark Office		ent and	
	Commissioner for 20231.	Patents, Washington, D.C.	<u>M</u> Signatu	aria K	Valen	th	
Date:	December	6 200	Maria l	P Volinch			

(Amendment Transmittal—page 1 of 4)

(type or print name of person certifying)

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of December 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings, and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.

3.	The proceeding	s herein are for a	patent application a	nd the provisions of	37 C.F.R. 1.136 apply

(complete (a) or (b), as applicable)

(a) [X] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity	Fee for small entity
r 1	one month	\$110.00	\$55.00
ii	two months	\$380.00	\$190.00
Ϊĺ	three months	\$870.00	\$435.00
[]	four months	\$1360.00	\$680.00

Fee: \$____

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

[]	An ex \$ reque	tension formonths has already been secured. The fee paid therefor of is deducted from the total fee due for the total months of extension now sted.
		Extension fee due with this request \$
		OR
(b)	[]	Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below: OTHER THAN A (Col. 2) (Col. 3) SMALL ENTITY **SMALL ENTITY** (Col.1) Claims Remaining Highest No. Previously Addit. Addit. After Present ORAmendment Paid For Extra Rate Fee Rate Fee Total x \$11 =x \$22 =Minus *** Indep. x \$41 =x \$82 =Minus First Presentation of Multiple Dependent Claim + \$135 = \$+ \$270 =Total OR Total Addit. Fee \$_ Addit. Fee \$_ If the entry in Col. 1 is less than the entry in Col. 2, write "O" in Col. 3, If the "Highest No. Previously Paid For" IN THIS SPACE is less than 20, enter "20". If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed. **WARNING:** "After final rejection or action (§ 1.113) amendments may be made canceling claims or complying with any requirement of form which has been made." 37 C.F.R. 1.116(a) (emphasis added). (complete (c) or (d), as applicable) (c) [X]No additional fee for claims is required. OR [] (d) Total additional fee for claims required \$______. **FEE PAYMENT** Attached is a check in the sum of \$___ 5. [] [] Charge Account No. A duplicate of this transmittal is attached.

FEE DEFICIENCY

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6. [X] If any additional extension and/or fee is required, charge Account No. __50-0850. AND/OR If any additional fee for claims is required, charge Account No. <u>50-0850</u> [X] SIGNATURE OF PRACTITIONER Reg. No. 30,628 Ronald I. Eisenstein type or print name of practitioner) Nixon Peabody LLP 101 Federal Street Tel. No. (617) 345-6054 P.O. Address

Boston, Massachusetts 02110

Customer No.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	In	re	app	lication	of:
-----------------------	----	----	-----	----------	-----

W. Marasco, et al.

Serial No.:

09/522,727

Group No.:

1644

Filed:

March 10, 2000

Examiner

Roark, J.

For:

INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

Ø	deposited with the United States Postal Service Washington, D.C. 20231.	in an envelope a	ddressed to the Assistant Commissioner for Patents,
	37 C.F.R. 1.8(a)		37 C.F.R. 1.10*
X	with sufficient postage as first class mail.		as "Express Mail Post Office to Address" Mailing Label No (mandatory)
	TRA	ANSMISSION	
	transmitted by facsimile to the Patent and Tradema	m	aria R. Welinch
Date: <u>/</u>	2/6/00		R. Valinch r print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Submission-Nucleotide and/or Amino Acid Sequence—page 1 of 3)



Docket No. 157-47577-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

W. Marasco, et al.

Serial No.:

09/522,727

Group No.:

1644

Filed:

March 10, 2000

Examiner

Roark, J.

For:

INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL OF SUBSTITUTE SPECIFICATION SHEETS (37 C.F.R. § 1.125)

NOTE: A substitute specification, excluding the claims, may be filed at any point up to payment of the issue fee if it is accompanied by items indicated below. See 37 C.F.R. § 1.125(b).

1. Enclosed are substitute specification sheets 44-65 for pages 44-46 of the originally filed specification in this application.

NOTE: The substitute specification must be submitted in clean form without markings as to amended material. 37 C.F.R. § 1.125(c).

2. *(complete the following applicable item)*

[X] This substitute specification is submitted, in response to a requirement by the Examiner. Namely, filing of SEQUENCE LISTING.

OR

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

FACSIMILE

transmitted by facsimile to the Patent and

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Trademark Office.

Signature

Date: December 6, 2000

Maria R. Valinch

(type or print name of person certifying)

(Transmittal of Substitute Specification-page 1 of 2)

[] This substitute specification is being voluntarily submitted, in order to facilitate the processing of the application.

3. As required by 37 C.F.R. § 1.125, the undersigned states that the substitute specification transmitted herewith contains no new matter.

| Conclude Language | Content |

Customer No.

Boston, Massachusetts 02110